Skip to main content
Erschienen in: Clinical Orthopaedics and Related Research® 3/2015

01.03.2015 | Symposium: 2013 Meetings of the Musculoskeletal Tumor Society and the International Society of Limb Salvage

Does Competing Risk Analysis Give Useful Information About Endoprosthetic Survival in Extremity Osteosarcoma?

verfasst von: Reinhard Schuh, MD, Alexandra Kaider, MSc, Reinhard Windhager, MD, Philipp T. Funovics, MD

Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Conventional survival analysis for endoprosthetic complications does not consider competing events adequately. Patients who die of their disease are no longer at risk for complications; therefore, death as a competing event may alter survivorship estimates in the orthopaedic-oncological setting.

Questions/purposes

This investigation aimed to compare (1) endoprosthetic survivorship after osteosarcoma by Kaplan-Meier analysis; and (2) by a competing risk model.

Methods

Between 1981 and 2009, we performed 247 modular endoprostheses for patients with extremity osteosarcoma; 73 patients had a followup of less than 2 years but all patients were included in statistical analysis. No patients were lost to followup for reasons other than death. Revision-free endoprosthetic survival until soft tissue failure (Type 1), aseptic loosening (Type 2), structural failure (Type 3), infection (Type 4), and local tumor progression (Type 5) was estimated according to a Kaplan-Meier analysis and a competing risk model. Sixty-four patients died throughout followup; the 5- and 10-year overall survival and metastasis-free survival were 72% and 70% and 70% and 69%, respectively. One hundred twenty-two patients (49%) had complications.

Results

Competing risk analysis consistently resulted in reduced estimates of the frequency of complications and reconstructive failures compared with Kaplan-Meier analysis. Cumulative risks for complication Types 1 to 5 at 10 years without/with death as a competing event revealed a risk of 19%/16% for Type 1, 26%/20% for Type 2, 51%/38% for Type 3, 23%/20% for Type 4, and 4%/3% for Type 5.

Conclusions

A competing risk model reveals considerably reduced risks for every complication compared with Kaplan-Meier analysis when death is included as a competing event. Because it more realistically represents the risks of complications, competing risk models should be used to arrive at risk estimates for purposes of counseling patients about those risks associated with modular endoprosthetic reconstruction.

Level of Evidence

Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
Literatur
1.
Zurück zum Zitat Biau D, Faure F, Katsahian S, Jeanrot C, Tomeno B, Anract P. Survival of total knee replacement with a megaprosthesis after bone tumor resection. J Bone Joint Surg Am. 2006;88:1285–1293.PubMedCrossRef Biau D, Faure F, Katsahian S, Jeanrot C, Tomeno B, Anract P. Survival of total knee replacement with a megaprosthesis after bone tumor resection. J Bone Joint Surg Am. 2006;88:1285–1293.PubMedCrossRef
3.
Zurück zum Zitat Biau DJ, Latouche A, Porcher R. Competing events influence estimated survival probability: when is Kaplan-Meier analysis appropriate? Clin Orthop Relat Res. 2007;462:229–233.PubMedCrossRef Biau DJ, Latouche A, Porcher R. Competing events influence estimated survival probability: when is Kaplan-Meier analysis appropriate? Clin Orthop Relat Res. 2007;462:229–233.PubMedCrossRef
4.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.PubMedCrossRef Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.PubMedCrossRef
5.
Zurück zum Zitat Dominkus M, Sabeti M, Toma C, Abdolvahab F, Trieb K, Kotz RI. Reconstructing the extensor apparatus with a new polyester ligament. Clin Orthop Relat Res. 2006;453:328–334.PubMedCrossRef Dominkus M, Sabeti M, Toma C, Abdolvahab F, Trieb K, Kotz RI. Reconstructing the extensor apparatus with a new polyester ligament. Clin Orthop Relat Res. 2006;453:328–334.PubMedCrossRef
6.
Zurück zum Zitat Funovics PT, Schuh R, Adams SB Jr, Sabeti-Aschraf M, Dominkus M, Kotz RI. Modular prosthetic reconstruction of major bone defects of the distal end of the humerus. J Bone Joint Surg Am. 2011;93:1064–1074.PubMedCrossRef Funovics PT, Schuh R, Adams SB Jr, Sabeti-Aschraf M, Dominkus M, Kotz RI. Modular prosthetic reconstruction of major bone defects of the distal end of the humerus. J Bone Joint Surg Am. 2011;93:1064–1074.PubMedCrossRef
7.
Zurück zum Zitat Gosheger G, Gebert C, Ahrens H, Streitbuerger A, Winkelmann W, Hardes J. Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res. 2006;450:164–171.PubMedCrossRef Gosheger G, Gebert C, Ahrens H, Streitbuerger A, Winkelmann W, Hardes J. Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res. 2006;450:164–171.PubMedCrossRef
8.
Zurück zum Zitat Hamadouche M, Boutin P, Daussange J, Bolander ME, Sedel L. Alumina-on-alumina total hip arthroplasty: a minimum 18.5-year follow-up study. J Bone Joint Surg Am. 2002;84:69–77.PubMed Hamadouche M, Boutin P, Daussange J, Bolander ME, Sedel L. Alumina-on-alumina total hip arthroplasty: a minimum 18.5-year follow-up study. J Bone Joint Surg Am. 2002;84:69–77.PubMed
9.
Zurück zum Zitat Henderson ER, Groundland JS, Pala E, Dennis JA, Wooten R, Cheong D, Windhager R, Kotz RI, Mercuri M, Funovics PT, Hornicek FJ, Temple HT, Ruggieri P, Letson GD. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011;93:418–429.PubMedCrossRef Henderson ER, Groundland JS, Pala E, Dennis JA, Wooten R, Cheong D, Windhager R, Kotz RI, Mercuri M, Funovics PT, Hornicek FJ, Temple HT, Ruggieri P, Letson GD. Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011;93:418–429.PubMedCrossRef
11.
Zurück zum Zitat Kotz R. [Tumor endoprosthesis in malignant bone tumors] [in German]. Der Orthopade. 1993;22:160–166.PubMed Kotz R. [Tumor endoprosthesis in malignant bone tumors] [in German]. Der Orthopade. 1993;22:160–166.PubMed
12.
Zurück zum Zitat Lazo-Langner A, Rodger MA, Barrowman NJ, Ramsay T, Wells PS, Coyle DA. Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis. BMC Med Res Methodol. 2012;12:3.PubMedCentralPubMedCrossRef Lazo-Langner A, Rodger MA, Barrowman NJ, Ramsay T, Wells PS, Coyle DA. Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis. BMC Med Res Methodol. 2012;12:3.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, Butterfass-Bahloul T, Calaminus G, Bernstein M. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res. 2009;152:339–353.PubMedCrossRef Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, Butterfass-Bahloul T, Calaminus G, Bernstein M. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res. 2009;152:339–353.PubMedCrossRef
14.
Zurück zum Zitat Mittermayer F, Krepler P, Dominkus M, Schwameis E, Sluga M, Heinzl H, Kotz R. Long-term followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop Relat Res. 2001;388:167–177.PubMedCrossRef Mittermayer F, Krepler P, Dominkus M, Schwameis E, Sluga M, Heinzl H, Kotz R. Long-term followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop Relat Res. 2001;388:167–177.PubMedCrossRef
15.
Zurück zum Zitat Mittermayer F, Windhager R, Dominkus M, Krepler P, Schwameis E, Sluga M, Kotz R, Strasser G. Revision of the Kotz type of tumour endoprosthesis for the lower limb. J Bone Joint Surg Br. 2002;84:401–406PubMedCrossRef Mittermayer F, Windhager R, Dominkus M, Krepler P, Schwameis E, Sluga M, Kotz R, Strasser G. Revision of the Kotz type of tumour endoprosthesis for the lower limb. J Bone Joint Surg Br. 2002;84:401–406PubMedCrossRef
16.
Zurück zum Zitat Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–2430.PubMedCrossRef Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–2430.PubMedCrossRef
18.
Zurück zum Zitat Ritschl P, Capanna R, Helwig U, Campanacci M, Kotz R. [KMFTR (Kotz Modular Femur Tibia Reconstruction System) modular tumor endoprosthesis system for the lower extremity] [in German]. Z Orthop Ihre Grenzgeb. 1992;130:290–293.PubMedCrossRef Ritschl P, Capanna R, Helwig U, Campanacci M, Kotz R. [KMFTR (Kotz Modular Femur Tibia Reconstruction System) modular tumor endoprosthesis system for the lower extremity] [in German]. Z Orthop Ihre Grenzgeb. 1992;130:290–293.PubMedCrossRef
19.
Zurück zum Zitat Schwartz AJ, Kabo JM, Eilber FC, Eilber FR, Eckardt JJ. Cemented distal femoral endoprostheses for musculoskeletal tumor: improved survival of modular versus custom implants. Clin Orthop Relat Res. 2010;468:2198–2210.PubMedCentralPubMedCrossRef Schwartz AJ, Kabo JM, Eilber FC, Eilber FR, Eckardt JJ. Cemented distal femoral endoprostheses for musculoskeletal tumor: improved survival of modular versus custom implants. Clin Orthop Relat Res. 2010;468:2198–2210.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381–387.PubMedCrossRef Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381–387.PubMedCrossRef
21.
Zurück zum Zitat Winkler K, Bielack SS, Delling G, Jurgens H, Kotz R, Salzer-Kuntschik M. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat Res. 1993;62:269–277.PubMedCrossRef Winkler K, Bielack SS, Delling G, Jurgens H, Kotz R, Salzer-Kuntschik M. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat Res. 1993;62:269–277.PubMedCrossRef
Metadaten
Titel
Does Competing Risk Analysis Give Useful Information About Endoprosthetic Survival in Extremity Osteosarcoma?
verfasst von
Reinhard Schuh, MD
Alexandra Kaider, MSc
Reinhard Windhager, MD
Philipp T. Funovics, MD
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Clinical Orthopaedics and Related Research® / Ausgabe 3/2015
Print ISSN: 0009-921X
Elektronische ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-014-3703-x

Weitere Artikel der Ausgabe 3/2015

Clinical Orthopaedics and Related Research® 3/2015 Zur Ausgabe

Symposium: 2013 Meetings of the Musculoskeletal Tumor Society and the International Society of Limb Salvage

Should Fractures in Massive Intercalary Bone Allografts of the Lower Limb Be Treated With ORIF or With a New Allograft?

Symposium: Advances in UHMWPE Biomaterials

Editorial Comment: Advances in UHMWPE Biomaterials

Symposium: 2013 Meetings of the Musculoskeletal Tumor Society and the International Society of Limb Salvage

Editorial Comment: 2013 Meetings of the Musculoskeletal Tumor Society and the International Society of Limb Salvage

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.